FDA Accepts Resubmitted NDA for Arimoclomol for Niemann-Pick

FDA Accepts Resubmitted NDA for Arimoclomol for Niemann-Pick Disease Type C

The FDA has accepted the resubmitted New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease type C.

Related Keywords

, Drug Administration , European Union , New Drug Application , Complete Response Letter , Severity Scale ,

© 2025 Vimarsana